Blog

Evan Levine, CEO of PsyBio Therapeutics, Sits in the Investor Hotseat on October 13th

Oct 7 • 2 min read

PsyBio Therapeutics ($PSYB) CEO, Evan Levine, joins the Investor Hotseat to field hot questions from host, Dustin Robinson of Iter Investments. Psybio has developed a portfolio of bio-medical chemistry development psycho-targeted compounds for the potential treatment for mental and neurological health. Evan himself is a leader encompassing more than two decades of in-depth expertise in…

Cybin Provides Update on its Intellectual Property Portfolio

Oct 7 • 3 min read

Cybin Inc. (NEO:CYBN | NYSE AMERICAN:CYBN)), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics®, is pleased to provide an update on its intellectual property progress in support of its research and development strategy. The Company continues to prioritize the development of in-house IP and licensing opportunities that support its active development programs and future novel…

Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

Oct 7 • 3 min read

Revive Therapeutics Ltd. (OTCQB: RVVTFC | SE: RVV | FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, today announced an update on the Company’s U.S. Food & Drug Administration Phase 3 clinical trial (the “Study”) (NCT04504734) to evaluate the safety and efficacy of…

PharmAla Biotech ready to assist Alberta Government with Clinical MDMA supply

Oct 6 • 3 min read

PharmAla Biotech (CSE: MDMA), currently the only manufacturer of GMP MDMA in Canada, stands ready to assist the Government of Alberta in supplying patients with clinical-grade drug product. However, many questions remain about how the Alberta government intends to deliver psychedelic molecules to patients under this new framework “As the only manufacturer of clinical-grade MDMA in North America we are completely committed to…

The MindMed Chronicles: Part 2 of the Interview with Jake Freeman of Freeman Capital

Oct 6 • 2 min read

The following is a continuation of all our recent MindMed coverage. Last week, we published the first conversation with Jake Freeman. Click here to watch part 1 of the Jake Freeman interview. Before that, it all began with a two-part interview with Dr. Scott Freeman in August. Click here to watch part 1 of the…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441442443444445446447448449450451452453454455456457458459460461462463464465466467468469470471472473474475476477478479480481482483484485486487488489490491492493494495496497498499500501502503504505506507508509510511512513514515516517518519520521522523524525526527528529530531532533534535536537538539540541542543544545546547548